Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan

As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in J...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2022-01, Vol.28 (1), p.116-119
Main Authors: Saita, Mizue, Yan, Yan, Ito, Kanami, Sasano, Hiroshi, Seyama, Kuniaki, Naito, Toshio
Format: Article
Language:English
Subjects:
Adverse reaction
BNT162b2
COVID-19 vaccine
Japan
Reactogenicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3
cites cdi_FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3
container_end_page 119
container_issue 1
container_start_page 116
container_title Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
container_volume 28
creator Saita, Mizue
Yan, Yan
Ito, Kanami
Sasano, Hiroshi
Seyama, Kuniaki
Naito, Toshio
description As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in Japan received two doses of the Pfizer-BioNTech vaccine from March 17 to May 19, 2021. Online questionnaires were distributed to registered recipients following each dose, from day 0 through day 8. Primary outcomes are the frequency of reactogenicity including local and systemic reactions. Length of absence from work was also analyzed. Most recipients self-reported reactogenicity after the first dose (97.3%; n = 3254; mean age [36.4]) and after the second dose (97.2%; n = 3165; mean age [36.5]). Systemic reactions following the second dose were substantially higher than the first dose, especially for fever (OR, 27.38; 95% CI, [22.00–34.06]; p 
doi_str_mv 10.1016/j.jiac.2021.09.009
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8443338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X21002580</els_id><sourcerecordid>2577458389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3</originalsourceid><addsrcrecordid>eNp9kUuLFDEUhYMozkP_gKss3VRNHvVIRISxfY0MMzCM4i6kklvdaauSNkl3Mxt_u2l6ENy4urmce77AOQi9oqSmhHYX63rttKkZYbQmsiZEPkGntOF91feCPC1v3tCKM_rjBJ2ltCaE9q0Qz9EJb1pRNnqKft-BNjkswTvj8gMewzSFvfNLnPcB25Ag4TDivAL8_uaedmxgeL67ucSL2-9XHyoq8U4b4zy8wYU0VfsQJ4th5yx4A3iMYcarIuSV0RFwkX9CTNh5_FVvtH-Bno16SvDycZ6jb58-3i--VNe3n68Wl9eVaRnLVc94w0fTE-jA6K7pOGcdMKblQEAKC5rKwXI-cmGHnraCc26GToKUxmit-Tl6d-RutsMM1oDPUU9qE92s44MK2ql_Fe9Wahl2SjRNYYkCeP0IiOHXFlJWs0sGpkl7CNukWNv3JVQuZDllx1MTQ0oRxr_fUKIOxam1OhSnDsUpIlUprpjeHk1QUtg5iCoZd4jQuggmKxvc_-x_AASdoQM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2577458389</pqid></control><display><type>article</type><title>Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan</title><source>ScienceDirect Freedom Collection</source><creator>Saita, Mizue ; Yan, Yan ; Ito, Kanami ; Sasano, Hiroshi ; Seyama, Kuniaki ; Naito, Toshio</creator><creatorcontrib>Saita, Mizue ; Yan, Yan ; Ito, Kanami ; Sasano, Hiroshi ; Seyama, Kuniaki ; Naito, Toshio</creatorcontrib><description>As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in Japan received two doses of the Pfizer-BioNTech vaccine from March 17 to May 19, 2021. Online questionnaires were distributed to registered recipients following each dose, from day 0 through day 8. Primary outcomes are the frequency of reactogenicity including local and systemic reactions. Length of absence from work was also analyzed. Most recipients self-reported reactogenicity after the first dose (97.3%; n = 3254; mean age [36.4]) and after the second dose (97.2%; n = 3165; mean age [36.5]). Systemic reactions following the second dose were substantially higher than the first dose, especially for fever (OR, 27.38; 95% CI, [22.00–34.06]; p &lt; 0.001), chills (OR, 16.49; 95% CI, [13.53–20.11]; p &lt; 0.001), joint pain (OR, 8.49; 95% CI, [7.21–9.99]; p &lt; 0.001), fatigue (OR, 7.18; 95% CI, [6.43–8.02]; p &lt; 0.001) and headache (OR, 5.43; 95% CI, [4.80–6.14]; p &lt; 0.001). Reactogenicity was more commonly seen in young, female groups. 19.3% of participants took days off from work after the second dose (2.2% after the first dose), with 4.7% absent for more than two days. Although most participants reported reactogenicity, severe cases were limited. This study provides real-world evidence for the general population and organizations to prepare for BNT162b2 mRNA COVID-19 vaccination in Japan and other countries in the region.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2021.09.009</identifier><identifier>PMID: 34580011</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>Adverse reaction ; BNT162b2 ; COVID-19 vaccine ; Japan ; Reactogenicity</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-01, Vol.28 (1), p.116-119</ispartof><rights>2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><rights>2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3</citedby><cites>FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3</cites><orcidid>0000-0002-6272-0439 ; 0000-0003-1646-9930</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Saita, Mizue</creatorcontrib><creatorcontrib>Yan, Yan</creatorcontrib><creatorcontrib>Ito, Kanami</creatorcontrib><creatorcontrib>Sasano, Hiroshi</creatorcontrib><creatorcontrib>Seyama, Kuniaki</creatorcontrib><creatorcontrib>Naito, Toshio</creatorcontrib><title>Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><description>As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in Japan received two doses of the Pfizer-BioNTech vaccine from March 17 to May 19, 2021. Online questionnaires were distributed to registered recipients following each dose, from day 0 through day 8. Primary outcomes are the frequency of reactogenicity including local and systemic reactions. Length of absence from work was also analyzed. Most recipients self-reported reactogenicity after the first dose (97.3%; n = 3254; mean age [36.4]) and after the second dose (97.2%; n = 3165; mean age [36.5]). Systemic reactions following the second dose were substantially higher than the first dose, especially for fever (OR, 27.38; 95% CI, [22.00–34.06]; p &lt; 0.001), chills (OR, 16.49; 95% CI, [13.53–20.11]; p &lt; 0.001), joint pain (OR, 8.49; 95% CI, [7.21–9.99]; p &lt; 0.001), fatigue (OR, 7.18; 95% CI, [6.43–8.02]; p &lt; 0.001) and headache (OR, 5.43; 95% CI, [4.80–6.14]; p &lt; 0.001). Reactogenicity was more commonly seen in young, female groups. 19.3% of participants took days off from work after the second dose (2.2% after the first dose), with 4.7% absent for more than two days. Although most participants reported reactogenicity, severe cases were limited. This study provides real-world evidence for the general population and organizations to prepare for BNT162b2 mRNA COVID-19 vaccination in Japan and other countries in the region.</description><subject>Adverse reaction</subject><subject>BNT162b2</subject><subject>COVID-19 vaccine</subject><subject>Japan</subject><subject>Reactogenicity</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kUuLFDEUhYMozkP_gKss3VRNHvVIRISxfY0MMzCM4i6kklvdaauSNkl3Mxt_u2l6ENy4urmce77AOQi9oqSmhHYX63rttKkZYbQmsiZEPkGntOF91feCPC1v3tCKM_rjBJ2ltCaE9q0Qz9EJb1pRNnqKft-BNjkswTvj8gMewzSFvfNLnPcB25Ag4TDivAL8_uaedmxgeL67ucSL2-9XHyoq8U4b4zy8wYU0VfsQJ4th5yx4A3iMYcarIuSV0RFwkX9CTNh5_FVvtH-Bno16SvDycZ6jb58-3i--VNe3n68Wl9eVaRnLVc94w0fTE-jA6K7pOGcdMKblQEAKC5rKwXI-cmGHnraCc26GToKUxmit-Tl6d-RutsMM1oDPUU9qE92s44MK2ql_Fe9Wahl2SjRNYYkCeP0IiOHXFlJWs0sGpkl7CNukWNv3JVQuZDllx1MTQ0oRxr_fUKIOxam1OhSnDsUpIlUprpjeHk1QUtg5iCoZd4jQuggmKxvc_-x_AASdoQM</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Saita, Mizue</creator><creator>Yan, Yan</creator><creator>Ito, Kanami</creator><creator>Sasano, Hiroshi</creator><creator>Seyama, Kuniaki</creator><creator>Naito, Toshio</creator><general>Elsevier Ltd</general><general>Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6272-0439</orcidid><orcidid>https://orcid.org/0000-0003-1646-9930</orcidid></search><sort><creationdate>20220101</creationdate><title>Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan</title><author>Saita, Mizue ; Yan, Yan ; Ito, Kanami ; Sasano, Hiroshi ; Seyama, Kuniaki ; Naito, Toshio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adverse reaction</topic><topic>BNT162b2</topic><topic>COVID-19 vaccine</topic><topic>Japan</topic><topic>Reactogenicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saita, Mizue</creatorcontrib><creatorcontrib>Yan, Yan</creatorcontrib><creatorcontrib>Ito, Kanami</creatorcontrib><creatorcontrib>Sasano, Hiroshi</creatorcontrib><creatorcontrib>Seyama, Kuniaki</creatorcontrib><creatorcontrib>Naito, Toshio</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saita, Mizue</au><au>Yan, Yan</au><au>Ito, Kanami</au><au>Sasano, Hiroshi</au><au>Seyama, Kuniaki</au><au>Naito, Toshio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><date>2022-01-01</date><risdate>2022</risdate><volume>28</volume><issue>1</issue><spage>116</spage><epage>119</epage><pages>116-119</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in Japan received two doses of the Pfizer-BioNTech vaccine from March 17 to May 19, 2021. Online questionnaires were distributed to registered recipients following each dose, from day 0 through day 8. Primary outcomes are the frequency of reactogenicity including local and systemic reactions. Length of absence from work was also analyzed. Most recipients self-reported reactogenicity after the first dose (97.3%; n = 3254; mean age [36.4]) and after the second dose (97.2%; n = 3165; mean age [36.5]). Systemic reactions following the second dose were substantially higher than the first dose, especially for fever (OR, 27.38; 95% CI, [22.00–34.06]; p &lt; 0.001), chills (OR, 16.49; 95% CI, [13.53–20.11]; p &lt; 0.001), joint pain (OR, 8.49; 95% CI, [7.21–9.99]; p &lt; 0.001), fatigue (OR, 7.18; 95% CI, [6.43–8.02]; p &lt; 0.001) and headache (OR, 5.43; 95% CI, [4.80–6.14]; p &lt; 0.001). Reactogenicity was more commonly seen in young, female groups. 19.3% of participants took days off from work after the second dose (2.2% after the first dose), with 4.7% absent for more than two days. Although most participants reported reactogenicity, severe cases were limited. This study provides real-world evidence for the general population and organizations to prepare for BNT162b2 mRNA COVID-19 vaccination in Japan and other countries in the region.</abstract><pub>Elsevier Ltd</pub><pmid>34580011</pmid><doi>10.1016/j.jiac.2021.09.009</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6272-0439</orcidid><orcidid>https://orcid.org/0000-0003-1646-9930</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1341-321X
ispartof Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-01, Vol.28 (1), p.116-119
issn 1341-321X
1437-7780
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8443338
source ScienceDirect Freedom Collection
subjects Adverse reaction
BNT162b2
COVID-19 vaccine
Japan
Reactogenicity
title Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T18%3A14%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reactogenicity%20following%20two%20doses%20of%20the%20BNT162b2%20mRNA%20COVID-19%20vaccine:%20Real-world%20evidence%20from%20healthcare%20workers%20in%20Japan&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Saita,%20Mizue&rft.date=2022-01-01&rft.volume=28&rft.issue=1&rft.spage=116&rft.epage=119&rft.pages=116-119&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2021.09.009&rft_dat=%3Cproquest_pubme%3E2577458389%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c522t-72343fc70e6eca6463326e22a9b0e98dea19bd33f38db7158333cb69e99ccaaa3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2577458389&rft_id=info:pmid/34580011&rfr_iscdi=true